Summary
Agilent Technologies, Inc. reported a 5% decrease in net revenue for the fiscal year ended October 31, 2024, reaching $6.51 billion. This decline was primarily attributed to weakened customer capital expenditure spending, impacting both the Life Sciences and Applied Markets and Diagnostics and Genomics segments, particularly within the pharmaceutical sector. However, the Agilent CrossLab segment demonstrated resilience with a 5% revenue increase, driven by strong demand for repair and maintenance services across all end markets. The company maintained profitability with net income of $1.29 billion, slightly up from the previous year, supported by cost-saving initiatives and higher interest income. Agilent also completed a significant acquisition of BIOVECTRA for $915 million, expanding its contract development and manufacturing capabilities. The company continues to focus on enhancing customer experience and driving productivity, anticipating a gradual recovery in customer capital budgets while managing inflationary pressures through pricing strategies and cost-saving measures.
Financial Highlights
57 data points| Revenue | $6.51B |
| Cost of Revenue | $2.98B |
| Gross Profit | $3.54B |
| R&D Expenses | $479.00M |
| SG&A Expenses | $1.57B |
| Operating Expenses | $5.02B |
| Operating Income | $1.49B |
| Interest Expense | $96.00M |
| Net Income | $1.29B |
| EPS (Basic) | $4.44 |
| EPS (Diluted) | $4.43 |
| Shares Outstanding (Basic) | 290.00M |
| Shares Outstanding (Diluted) | 291.00M |
Key Highlights
- 1Net revenue for fiscal year 2024 decreased by 5% to $6.51 billion, compared to $6.83 billion in fiscal year 2023.
- 2The Life Sciences and Applied Markets segment saw an 8% revenue decline, while the Diagnostics and Genomics segment experienced a 6% decrease.
- 3The Agilent CrossLab segment reported a 5% revenue increase, indicating resilience in its services portfolio.
- 4Net income remained strong at $1.29 billion, a slight increase from $1.24 billion in fiscal year 2023.
- 5The company acquired BIOVECTRA for $915 million, significantly expanding its contract development and manufacturing organization (CDMO) capabilities.
- 6Agilent repurchased $1.15 billion of its common stock during fiscal year 2024, demonstrating a commitment to returning capital to shareholders.
- 7Restructuring expenses totaled $76 million in fiscal year 2024, primarily related to workforce reductions and facility consolidations aimed at cost reduction.